Do Patients Consider Preoperative Chemoradiation for Primary Rectal Cancer Worthwhile?
Overview
Authors
Affiliations
Background: The objective of this study was to elicit future patients' preferences for preoperative chemoradiation (pre-CRT) for rectal cancer to determine whether patients' preferences are consistent with current treatment guidelines.
Methods: During a standardized interview, the treatment protocol, risks, benefits, and long-term outcomes associated with 1) surgery alone (SA) and 2) pre-CRT followed by surgery (CR + S) were described to healthy individuals, and a threshold task was performed. Each participant was asked which treatment option they would prefer when the risk of local recurrence was set initially at 15% for both options. If the participant indicated SA (which was expected), then the risk of local recurrence for CR + S was lowered systematically until the participant's preference changed from SA to CR + S. This threshold point represented the risk of local recurrence for pre-CRT that the participant would require before they would choose treatment with pre-CRT.
Results: Fifty individuals participated in the study, and the majority were well educated. Twenty-seven of 50 participants (54%) required a risk of local recurrence with CR + S of ≤ 5% (ie, equivalent to an absolute risk reduction ≥ 10%) before they would choose treatment with pre-CRT. Regression analysis did not identify any variables that were predictive of the participants' preferences.
Conclusions: Participants seemed to highly value functional outcomes and seemed willing to accept a higher risk of local recurrence to achieve this. Therefore, developers of future guidelines may need to downgrade the use of pre-CRT for all patients with stage II/III tumors from a guideline to an option.
Dossa F, Weiser M Ann Surg Oncol. 2024; 31(10):6337-6341.
PMID: 39150616 DOI: 10.1245/s10434-024-16032-y.
Rectosigmoid Cancer-Rectal Cancer or Sigmoid Cancer?.
Hui C, Baclay R, Liu K, Sandhu N, Loo P, von Eyben R Am J Clin Oncol. 2022; 45(8):333-337.
PMID: 35848736 PMC: 9311454. DOI: 10.1097/COC.0000000000000931.
Qin Q, Wang L J Anus Rectum Colon. 2019; 2(2):47-58.
PMID: 31583321 PMC: 6768820. DOI: 10.23922/jarc.2017-049.
Kennedy E, Simunovic M, Jhaveri K, Kirsch R, Brierley J, Drolet S JAMA Oncol. 2019; 5(7):961-966.
PMID: 30973610 PMC: 6583831. DOI: 10.1001/jamaoncol.2019.0186.
Kunneman M, Pieterse A, Stiggelbout A, Nout R, Kamps M, Lutgens L Br J Cancer. 2014; 111(4):674-9.
PMID: 24921911 PMC: 4134490. DOI: 10.1038/bjc.2014.322.